Kadmon Holdings, Inc. (KDMN) EPS Estimated At $-0.34; Universal Technical Institute (UTI) Has 0.95 Sentiment

March 1, 2018 - By wolcottdaily

Analysts expect Kadmon Holdings, Inc. (NYSE:KDMN) to report $-0.34 EPS on March, 28.They anticipate $0.16 EPS change or 32.00% from last quarter’s $-0.5 EPS. After having $-0.42 EPS previously, Kadmon Holdings, Inc.’s analysts see -19.05% EPS growth. The stock decreased 1.90% or $0.07 during the last trading session, reaching $3.61. About 821,746 shares traded. Kadmon Holdings, Inc. (NYSE:KDMN) has 0.00% since March 1, 2017 and is . It has underperformed by 16.70% the S&P500.

Universal Technical Institute, Inc. provides postsecondary education for students seeking careers as professional automotive, diesel, collision repair, motorcycle, and marine technicians in the United States. The company has market cap of $67.53 million. The firm offers undergraduate degree and diploma programs, and specialized technical education programs through its 12 campuses under various brands, such as Universal Technical Institute, Motorcycle Mechanics Institute and Marine Mechanics Institute, and NASCAR Technical Institute. It currently has negative earnings. It also provides maker specific advanced training programs, including student paid electives at its campuses; and maker or dealer sponsored training at various campuses and dedicated training centers.

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases. The company has market cap of $283.90 million. The firm markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. It currently has negative earnings. The Company’s lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of Wilson's disease, a genetic liver disease.

Among 6 analysts covering Kadmon Holdings (NYSE:KDMN), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Kadmon Holdings had 7 analyst reports since August 22, 2016 according to SRatingsIntel. The firm earned “Overweight” rating on Friday, March 24 by Piper Jaffray. H.C. Wainwright maintained Kadmon Holdings, Inc. (NYSE:KDMN) rating on Monday, June 26. H.C. Wainwright has “Buy” rating and $25 target. On Thursday, March 16 the stock rating was upgraded by WBB Securities to “Hold”. The stock has “Outperform” rating by JMP Securities on Monday, August 22. H.C. Wainwright initiated the shares of KDMN in report on Monday, August 22 with “Buy” rating. The stock of Kadmon Holdings, Inc. (NYSE:KDMN) earned “Buy” rating by Jefferies on Monday, August 22. The rating was initiated by Citigroup with “Neutral” on Monday, August 22.

Analysts await Universal Technical Institute, Inc. (NYSE:UTI) to report earnings on May, 3. They expect $-0.19 EPS, down 58.33% or $0.07 from last year’s $-0.12 per share. After $-0.21 actual EPS reported by Universal Technical Institute, Inc. for the previous quarter, Wall Street now forecasts -9.52% EPS growth.

It closed at $2.7 lastly. It is down 18.09% since March 1, 2017 and is uptrending. It has outperformed by 1.39% the S&P500.

Since January 1, 0001, it had 2 buys, and 0 insider sales for $34,466 activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: